Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam
Pharmaceuticals, Inc.
(Nasdaq: ALNY), the leading RNAi therapeutics
company, announced today that management will present a company overview
at the 37th Annual J.P. Morgan Healthcare Conference on
Monday, January 7, 2019 at 10:30 am PT (1:30 pm ET) at The Westin St.
Francis in San Francisco. This presentation will include an update on
unaudited fourth quarter 2018 global net product revenues for ONPATTRO®
(patisiran) as well as additional updates on the product’s commercial
launch. In addition, the Company will webcast the QA breakout session
immediately following its presentation at 11:00 am PT (2:00 pm ET).

A live audio webcast of both the presentation and breakout session will
be available on the Investors section of the Company’s website, www.alnylam.com.
A replay will be available on the Alnylam website within 48 hours after
the event.

About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system (CNS) diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
severe and debilitating diseases. Founded in 2002, Alnylam is delivering
on a bold vision to turn scientific possibility into reality, with a
robust discovery platform. Alnylam’s first U.S. FDA-approved RNAi
therapeutic is ONPATTRO™ (patisiran) lipid complex injection available
in the U.S. for the treatment of the polyneuropathy of hereditary
transthyretin-mediated (hATTR) amyloidosis in adults. In the EU,
ONPATTRO is approved for the treatment of hATTR amyloidosis in adults
with stage 1 or stage 2 polyneuropathy. Alnylam has a deep pipeline of
investigational medicines, including four product candidates that are in
late-stage development. Looking forward, Alnylam will continue to
execute on its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines to address the needs of patients who have
limited or inadequate treatment options. Alnylam employs over 1,000
people worldwide and is headquartered in Cambridge, MA. For more
information about our people, science and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.